Background

- ESRB, a cancer marker in the growth and metastasis of ERBB3 (erbB3) tumors
- ESRB is expressed at high levels in ERBB3 tumors
- ESRB is associated with poor prognosis in ERBB3 tumors

Methods

- The trial was a Phase I/II study of patients with metastatic or advanced solid tumors
- Patients were treated with AV-203, a monoclonal antibody against ERBB3
- Patients received AV-203 at escalating dose levels
- Safety and tolerability were assessed
- Efficacy was evaluated in patients with metastatic disease

Results

- 22 patients with various solid tumors were treated with AV-203
- 10 patients had objective responses
- 10 patients had stable disease
- 2 patients had disease progression

Conclusions

- AV-203 is a promising agent for the treatment of ERBB3-positive tumors
- Further studies are needed to evaluate the efficacy and safety of AV-203 in larger patient populations
- The study provides preliminary evidence of the potential of AV-203 as a therapeutic agent for ERBB3-positive tumors